One example, ABT-199 (Venetoclax), selectively targets BCL2, and, in recent clinical trials involving relapsed or refractory CLL, patients gave an overall response rate of 79% (Roberts et al., 2016). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.